Clear Focus offers promising potential in distributing CinG-XTM Capsules

January 16, 2013

Social media initiatives raise awareness for all natural treatment and preventative aid

TORONTO -- The growing response from mass market merchandisers, drug and grocery chains for CinG-XTM capsules is far surpassing the expectations of Allegiance Equity Corporation (Allegiance, TSXV: ANQ) and its distributor, Clear Focus International Inc (Clear Focus.) Allegiance and Clear Focus are in the preliminary stages of developing and establishing a distribution method; capsules are currently available on the online CinG-XTM store ( for $39.95 for a bottle of 60 capsules.

“Allegiance has long admired the power and success of Clear Focus,” says Allegiance’s CEO David Solomon, “I am positive, working with Clear Focus, that we will be able to distribute CinG-XTM across North America and succeed in making CinG-XTM a household name.”

Sales for products that regulate blood sugar and decrease memory loss exceed 140 billion a year, however most have limited benefits as well as side effects. This creates and provides a mass-market opportunity for the introduction of CinG-XTM capsules, by comparison it is effective and holds a favourable safety profile.

Clear Focus has received strong response from its customer base, such as Wal-Mart, Costco, Target, Walgreens, Kroger, BJ’s, CVS, Amazon, Safeway, Rite Aid, Publix, JC Penney, Sears, SuperValue, Army Air force Exchange, HEB supermarkets, Giant Eagle, Health Mart, Save Mart, Whole Foods, A&P, Marc’s Drug, Medicine Shoppe, USA Drug and many more throughout the USA.

Allegiance amplifies high public demand to its increasing attention to social media programs, which continuously generate new followers and peak the interest of the dissatisfied customers of Over the Counter (OTC) drugs. CinG-XTM offers these consumers an all-natural supplement that is unlike any on the market currently.

“It’s incredible the impact and difference social media can make for a corporation like [Allegiance]” says Solomon, “I’ve always known we’ve had a great product, one that is truly unique, but we now have the tools and mediums to tell Canada, and the world, the significance and power of CinG-XTM.”

CinG-XTM capsules include a proprietary formulation, containing cinnamon and Panax ginseng, in a patented ratio that reduces blood sugar and improves brain functions. The cinnamon acts as an insulin mimetic by activating insulin receptors on the body’s cell membranes, increasing the effect of insulin and further reducing insulin resistance. Cinnamon stimulates the enzymes that help store blood sugar as glycogen. These combine, resulting in lower blood sugar levels and greater storage of sugar in the liver. Panax Ginseng lowers blood glucose and stimulates insulin release. Ginseng is an adaptogen, it works through the adrenal glands to help the body adapt and cope with stresses, such as fatigue and anxiety, increasing oxygen uptake and related work load.

International PCT Patent Examiner, under Publication No. WO 2010/048705, favourably reviews the following claims for CinG-XTM in effective amounts, ratios, and dosages:

1. Improvement of cognitive function
2. Prevention and treatment of Alzheimer's disease
3. Prevention of arterial disease
4. Maintenance and lowering of blood sugar levels
5. Improvement of cognitive function in diabetics

Private Placement:

The Board of Directors of the Corporation has authorized a private placement to raise $370,000 by sale of common shares and warrants to be priced within the context of the market. Allegiance is in the early stages of discussing, with several potential investors, financing for the activities of the corporation.

The funding will be used for the following purposes:

- To capitalize on new opportunities for CING-X and Relieva, Allegiance’s two proprietary technologies
- To meet ongoing administrative and operational expenses

Interest of Management Notice of Intention to Distribute:

Palm American Investment Inc. (Palm American) currently holds 2,208,497 common shares and 700,000 common share purchase warrants of Allegiance. David Solomon, his wife Marilyn Bloovol, and members of their family control Palm American. Palm American is filing a Notice of Intention to sell up to 1,200,000 common shares on January 16, 2013 by way of private sale or on the market.

There are presently 8,341,087 common shares and 700,000 share purchase warrants of Allegiance issued and outstanding. It is anticipated that Palm American may participate in the proposed private placement.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy for this press release, which has been prepared by management.

About CinG-XTM:
CinG-XTM is a combination of standardized extracts acting synergistically to control glucose metabolism, improve cognitive function and reduce the risk of developing conditions associated with blood glucose metabolism and brain function. CinG-XTM has been approved by Health Canada and Master File OF12-21-26454-MF001 supports its claims. International PCT Patent Examiner has favourably reviewed CinG-XTM claims under the Publication No. WO 2010/048705.

About The CING-X Corporation:
Allegiance Equity Corporation (Allegiance Equity), Legacy Research Corporation (Legacy), and Collagenna Skin Care Products Inc (Collagenna) formulated and funded The CING-X Corporation to market the CinG-X capsules. Allegiance and Legacy each own a 25% equity share ownership in The CING-X Corporation in partnership with Collagenna.

About Allegiance Equity Corporation:
Allegiance Equity (ANQ.V) is a public company that develops unique standardized mass-market products for the treatment of common diseases where present pharmaceutical treatments and Over the Counter (OTC) products fail to meet the needs of patients.

Allegiance targets markets having clearly identified product deficiencies and dissatisfied consumers afflicted with common diseases and conditions including Alzheimer's, dementia, diabetes and inflammatory skin conditions, Allegiance obtains regulatory approval and patents for these unique compounds and formulations, for licensing, and royalty revenues.

For further information please contact:

David Solomon, President and CEO

Jordan Rints, Communications and Public Relations